Cargando…

Matrix Metalloproteinases in Diabetic Kidney Disease

Around the world diabetic kidney disease (DKD) is the main cause of chronic kidney disease (CKD), which is characterized by mesangial expansion, glomerulosclerosis, tubular atrophy, and interstitial fibrosis. The hallmark of the pathogenesis of DKD is an increased extracellular matrix (ECM) accumula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garcia-Fernandez, Nuria, Jacobs-Cachá, Conxita, Mora-Gutiérrez, José María, Vergara, Ander, Orbe, Josune, Soler, María José
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073625/ https://www.ncbi.nlm.nih.gov/pubmed/32046355 http://dx.doi.org/10.3390/jcm9020472

Ejemplares similares

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

Antioxidant Roles of SGLT2 Inhibitors in the Kidney
por: Llorens-Cebrià, Carmen, et al.
Publicado: (2022)

Association between Circulating Levels of 25-Hydroxyvitamin D(3) and Matrix Metalloproteinase-10 (MMP-10) in Patients with Type 2 Diabetes
por: Abasheva, Daria, et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease
por: Górriz, Jose Luis, et al.
Publicado: (2020)

The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes
por: García-Carro, Clara, et al.
Publicado: (2019)

Endothelin Receptor Antagonists in Kidney Disease
por: Martínez-Díaz, Irene, et al.
Publicado: (2023)

Effect of ramipril on kidney, lung and heart ACE2 in a diabetic mice model
por: Vergara, Ander, et al.
Publicado: (2021)

Revisiting Experimental Models of Diabetic Nephropathy
por: Giralt-López, Anna, et al.
Publicado: (2020)

MMP-10 is Increased in Early Stage Diabetic Kidney Disease and can be Reduced by Renin-Angiotensin System Blockade
por: Mora-Gutiérrez, José María, et al.
Publicado: (2020)

The COVID-19 pandemic: progress in nephrology
por: Soler, María José, et al.
Publicado: (2021)

Matrix Metalloproteinase 10 Contributes to Choroidal Neovascularisation
por: González-Zamora, Jorge, et al.
Publicado: (2022)

A Specific Tubular ApoA-I Distribution Is Associated to FSGS Recurrence after Kidney Transplantation
por: Jacobs-Cachá, Conxita, et al.
Publicado: (2021)

Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis
por: Lorente, Leonardo, et al.
Publicado: (2009)

Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers
por: Jacobs-Cachá, Conxita, et al.
Publicado: (2020)

Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice
por: Vergara, Ander, et al.
Publicado: (2022)

Urinary Extracellular Vesicles for Diabetic Kidney Disease Diagnosis
por: Saenz-Pipaon, Goren, et al.
Publicado: (2021)

Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction
por: Lorente, Leonardo, et al.
Publicado: (2015)

Association between Serum Tissue Inhibitor of Matrix Metalloproteinase-1 Levels and Mortality in Patients with Severe Brain Trauma Injury
por: Lorente, Leonardo, et al.
Publicado: (2014)

Perspectives on the Role of Magnetic Resonance Imaging (MRI) for Noninvasive Evaluation of Diabetic Kidney Disease
por: Mora-Gutiérrez, José María, et al.
Publicado: (2021)

Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)

How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR
por: García-Carro, Clara, et al.
Publicado: (2021)

High serum levels of tissue inhibitor of matrix metalloproteinase-1 during the first week of a malignant middle cerebral artery infarction in non-surviving patients
por: Lorente, Leonardo, et al.
Publicado: (2019)

Loss of the matrix metalloproteinase-10 causes premature features of aging in satellite cells
por: Bobadilla Muñoz, Miriam, et al.
Publicado: (2023)

A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management
por: García-Carro, Clara, et al.
Publicado: (2021)

The Many Faces of Matrix Metalloproteinase-7 in Kidney Diseases
por: Liu, Zhao, et al.
Publicado: (2020)

Matrix Metalloproteinase-10 in Kidney Injury Repair and Disease
por: Sun, Xiaoli, et al.
Publicado: (2022)

Matrix Metalloproteinases-7 and Kidney Fibrosis
por: Ke, Ben, et al.
Publicado: (2017)

Urinary Matrix Metalloproteinase Activity in Diabetic Kidney Disease: A Potential Marker of Disease Progression
por: Altemtam, Nagi, et al.
Publicado: (2012)

Matrix metalloproteinases and their inhibitors as biomarkers of severity in sepsis
por: Lorente, Leonardo, et al.
Publicado: (2010)

Corrigendum: Matrix Metalloproteinase-7 and Kidney Fibrosis
por: Ke, Ben, et al.
Publicado: (2017)

Integrating Soluble Biomarkers and Imaging Technologies in the Identification of Vulnerable Atherosclerotic Patients
por: Páramo, José A., et al.
Publicado: (2007)

Matrix Metalloproteinase-1 and Matrix Metalloproteinase-9 in the Aqueous Humor of Diabetic Macular Edema Patients
por: Kwon, Jin-woo, et al.
Publicado: (2016)

A misprocessed form of Apolipoprotein A-I is specifically associated with recurrent Focal Segmental Glomerulosclerosis
por: Jacobs-Cachá, Conxita, et al.
Publicado: (2020)

Matrix Metalloproteinases in Chronic Obstructive Pulmonary Disease
por: Christopoulou, Maria-Elpida, et al.
Publicado: (2023)

Matrix metalloproteinases in arthritic disease
por: Murphy, Gillian, et al.
Publicado: (2002)

Matrix Metalloproteinases in Health and Disease
por: Serra, Raffaele
Publicado: (2020)

Role of Extracellular Vesicles as Potential Diagnostic and/or Therapeutic Biomarkers in Chronic Cardiovascular Diseases
por: Martin-Ventura, Jose Luis, et al.
Publicado: (2022)

Matrix Metalloproteinases in Health and Disease in the Times of COVID-19
por: Fernandez-Patron, Carlos, et al.
Publicado: (2022)

Matrix metalloproteinases in subjects with type 1 diabetes
por: Gharagozlian, Sedegheh, et al.
Publicado: (2009)

Stage-Specific Action of Matrix Metalloproteinases Influences Progressive Hereditary Kidney Disease
por: Zeisberg, Michael, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_8b7f4esetso2cco8gk5js8dvrv